Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 09:00 am Sale |
2024-12-31 | 13G | Replimune Group, Inc. REPL |
Forbion Capital Fund III Cooperatief U.A. | 4,219,340 6.100% |
-895,781 (-17.51%) |
Filing History |
| 2024-11-14 07:00 am Sale |
2024-09-30 | 13G | Replimune Group, Inc. REPL |
Forbion Capital Fund III Cooperatief U.A. | 5,115,121 7.500% |
-76,500 (-1.47%) |
Filing History |
| 2024-02-14 07:21 am Purchase |
2023-12-31 | 13G | Replimune Group, Inc. REPL |
Forbion Capital Fund III Cooperatief U.A. | 5,191,621 8.700% |
76,500 (+1.50%) |
Filing History |
| 2024-02-14 07:21 am Sale |
2023-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN |
Forbion Capital Fund III Cooperatief U.A. | 3,369,275 14.200% |
-536 (-0.02%) |
Filing History |
| 2023-11-13 4:01 pm Purchase |
2023-10-31 | 13G | enGene Holdings Inc. Common Stock ENGN |
Forbion Capital Fund III Cooperatief U.A. | 3,369,811 14.200% |
3,369,811 (New Position) |
Filing History |
| 2021-02-16 06:36 am Unchanged |
2020-12-31 | 13G | Replimune Group, Inc. REPL |
Forbion Capital Fund III Cooperatief U.A. | 5,115,121 11.130% |
0 (Unchanged) |
Filing History |
| 2021-02-16 06:10 am Sale |
2020-12-31 | 13G | Milestone Pharmaceuticals Inc. MIST |
Forbion Capital Fund III Cooperatief U.A. | 0 0.000% |
-1,303,902 (Position Closed) |
Filing History |